The Food and Drug Administration has approved another injectable form of naloxone in the effort to control opioid deaths. Zimhi is a single-dose prefilled syringe containing 5 mg/0.5 mL of naloxone. Zimhi is administered subcutaneously or intramuscularly.Nurses should educate patients receiving opioids and their families on how to use Zimhi or other prescribed naloxone products.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/01.NAJ.0000820552.55044.dd | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Finding new ways to treat overdoses.
Elife
January 2025
Department of Pharmaceutical Sciences, University of Kentucky, Lexington, United States.
Reversing opioid overdoses in rats using a drug that does not enter the brain prevents the sudden and severe withdrawal symptoms associated with therapeutics that target the central nervous system.
View Article and Find Full Text PDFCohort profile: the provincial opioid agonist treatment cohort in Ontario, Canada.
Eur J Epidemiol
January 2025
Health Sciences North Research Institute, Sudbury, ON, Canada.
Background: Opioid Agonist Treatment (OAT) is the most effective intervention for opioid use disorder (OUD), but retention has decreased due to increasingly potent drugs like fentanyl. This cohort can be used retrospectively to observe trends in service utilization, healthcare integration, healthcare costs and patient outcomes. It also facilitates the design of observational studies to mimic a prospective design.
View Article and Find Full Text PDFLarge library docking of tangible molecules has revealed potent ligands across many targets. While make-on-demand libraries now exceed 75 billion enumerated molecules, their synthetic routes are dominated by a few reaction types, reducing diversity and inevitably leaving many interesting bioactive-like chemotypes unexplored. Here, we investigate the large-scale enumeration and targeted docking of isoquinuclidines.
View Article and Find Full Text PDFA novel, multi-component contingency management intervention in the context of a syndemic of drug-related harms in Glasgow, Scotland: First year of the 'WAND' initiative.
Addict Behav Rep
June 2025
School of Health and Life Sciences, Glasgow Caledonian University, Glasgow, UK.
Background: To address high levels of drug-related harms among people who inject drugs (PWID) in Glasgow, a novel contingency management intervention was developed to engage high-risk PWID with four harm reduction measures (known as the WAND initiative: ound care, ssessment of injecting, aloxone, and ried blood-spot test). Our aims were to assess if WAND engaged and re-engaged high-risk PWID.
Methods: Baseline data of WAND participants (n = 831) from 1st Sept-2020 to 30th Aug-2021 were analysed.
Perceived organizational support for the treatment of opioid use disorder and its association with primary care provider treatment willingness and medication prescribing.
J Subst Use Addict Treat
January 2025
Ohio University Heritage College of Osteopathic Medicine; Appalachian Institute to Advance Health Equity Science (ADVANCE), Athens, OH 45701, United States of America. Electronic address:
Introduction: Buprenorphine is a highly effective medication for opioid use disorder (MOUD; OUD), which can be prescribed alongside naloxone in the primary care setting as part of a harm reduction approach to OUD. Despite this potential, implementation challenges have limited adoption of MOUD. To address barriers at the organizational level, we need better tools to measure perceived organizational support for the treatment of OUD and use of MOUD in the primary care setting.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!